Skip to content
Triangle logo TriangleGet started
← Study library

NCT00096174 · REGISTRY CONDITION SEARCH

Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
COMPLETED
Registry last update
2023-06-29

RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Cetuximab may make the tumor cells more sensitive to radiation therapy and chemotherapy. Giving monoclonal antibody therapy together with chemoradiotherapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cetuximab and cisplatin together with radiation therapy works in treating patients with locally advanced or regional stage IV head and neck cancer that cannot be removed by surgery.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

2-year Progression-free Survival Rate

→

outcome · POSTED

2-year Overall Survival Rate

→

outcome · POSTED

Overall Response Rate

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Histologically confirmed squamous cell or undifferentiated carcinoma of the head and neck (excluding nasopharynx, paranasal sinus, and parotid gland) * Unresectable locally advanced or regional stage IV disease * No evidence of distant metastases * Must have demonstrable primary tumor site * Measurable disease * Unresectable disease * Meets the following criteria for unresectable disease by tumor site: * Hypopharynx, meeting 1 of the following criteria: * Extension across the midline of the posterior pharyngeal wall * Any evidence of fixation to the cervical spine * Larynx * Direct subglottic extension (\>3cm) into surrounding muscle or skin * Oral cavity * Lesion precluding functional reconstruction * Base of tongue, meeting 1 of the following criteria: * Extension into the root of the tongue * Patient refuses total glossectomy * Tonsillar area, meeting 1 of the following criteria: * Extension into pterygoid area as manifested by x-ray or trismus * Extension across midline of pharyngeal wall * Direct extension into soft tissue of the neck * Unilateral neck node metastases fixed to carotid artery, mastoid, base of skull, or cervical spine with any of the above tumors * Patients requiring total glossectomy are eligible * Age\>=18 years * ECOG Performance status of 0-1 * Adequate hematologic, renal, and hepatic function obtained \<=4 weeks prior to registration * Absolute neutrophil count ≥ 2,000/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 9.0 g/dL * Alkaline phosphatase ≤ 3 times normal * Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) ≤ 3 times normal * Bilirubin ≤ 1.5 mg/dL * Creatinine ≤ 1.2 mg/dL OR creatinine clearance ≥ 50 mL/min * Able to tolerate fluid load * At least 14 days since major surgery (including dental extraction) except percutaneous endoscopic gastrostomy (PEG) placement or mediport placement Exclusion Criteria: * Pregnant or nursing * Fertile patients do not use effective contraception * Patients who refuse surgery but whose tumors are technically resectable OR whose tumors are unresectable for medical reasons are not eligible * Disease metastases below the clavicles or elsewhere (M1) or with a postoperative recurrence * Prior excisional surgery of head and neck tumor * Prior radiotherapy to the head and neck region * Prior chemotherapy * Prior drugs that target the epidermal growth factor receptor pathway * Prior chimerized or murine monoclonal antibody * Active systemic infection * Known allergy to murine proteins * Severe chronic obstructive pulmonary disease requiring ≥ 3 hospitalizations within the past year * Myocardial infarction within the past 3 months * Uncontrolled congestive heart failure * Unstable or uncontrolled angina * Clinically apparent jaundice * Postoperative recurrence * Other malignancy within the past 3 years except resected basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other in situ tumors
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    * Cetuximab therapy: Patients receive an initial loading dose of cetuximab intravenously (IV) over 2 hours on day 1. Patients then receive cetuximab IV over 1 hour on days 8, 15, 22, 29, 36, 43, 50, and 57. * Chemoradiotherapy: Beginning on day 15 of cetuximab therapy, patients undergo radiotherapy once daily, 5 days a week, for at least 7 weeks. Patients also receive cisplatin IV over 1-2 hours on days 15, 36, and 57. * Cetuximab maintenance therapy: After the completion of chemoradiotherapy, patients continue to receive cetuximab IV over 1 hour once weekly for 6-12 months.
    intervention Names
    1. Biological: cetuximab C225
    2. Drug: cisplatin
    3. Radiation: radiation therapy
    label
    Cisplatin, C225, Radiation
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Cisplatin, C225, Radiation
    description
    400 mg/m\^2 IV over 120 minutes on Day 1, 250 mg/m\^2 IV over 60 minutes on Day 8, then weekly
    name
    cetuximab C225
    other Names
    1. Cetuximab
    2. Erbitux
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Cisplatin, C225, Radiation
    description
    75 mg/m\^2 IV over 30-60 minutes starting day 15 every 3 weeks \* 3 (Days 1, 22, and 43 of radiation therapy (RT))
    name
    cisplatin
    other Names
    1. Platinol
    2. Platinol-AQ
    3. CDDP
    4. DDP
    5. DACP
    6. Platinum
    7. cis-Platinum
    type
    DRUG
  3. arm Group Labels
    1. Cisplatin, C225, Radiation
    description
    RT 70 Gy / 35 starting Day 15, 200cGy / d \* 7 weeks (35 fractions)
    name
    radiation therapy
    type
    RADIATION
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
69
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Two-year progression-free survival rate was defined as the proportion of patients that were alive progression-free two years after registration into the study. Disease progression was assessed per modified RECIST criteria, and defined as at least a 20% increase in the sum of the longest diameters of target lesions, in either primary or nodal lesions, taking as reference the smallest sum longest diameter recorded since the baseline measurements, or the appearance of new lesions. Kaplan-Meier estimate of 2-year progression-free survival was calculated in the 60 eligible and treated patients.
    measure
    2-year Progression-free Survival Rate
    time Frame
    assessed every 3 months for 2 years
secondary Outcomes
  1. description
    Overall survival was defined as time from registration to death from any cause. Patients alive at last follow-up were censored. The 2-year overall survival rate was defined as the percentage of patients that were still alive two years after registration into the study. Kaplan-Meier estimate of 2-year overall survival was calculated in the 60 eligible and treated patients.
    measure
    2-year Overall Survival Rate
    time Frame
    assessed very 3 months for 2 years
  2. description
    Response was assessed per Response Evaluation in Solid Tumor (RECIST) criteria by physical assessment and CT. Overall response = complete response (CR) + partial response (PR). CR was defined as the disappearance of all target and non-target lesions. PR was defined as at least a 30% decrease in the sum of the longest diameters of target lesions, along with non-progressive disease of non-target lesions. Overall response rate (i.e., proportion of patients who had CR or PR) and the corresponding 90% confidence intervals were calculated for the 60 eligible and treated patients
    measure
    Overall Response Rate
    time Frame
    assessed after all chemoradiation therapy completed Week 9, then every 3 months on C225 maintenance therapy, and every 3 months for 2 years, every 6 months post-treatment 2 years from study entry
Full study description
brief Summary
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Cetuximab may make the tumor cells more sensitive to radiation therapy and chemotherapy. Giving monoclonal antibody therapy together with chemoradiotherapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cetuximab and cisplatin together with radiation therapy works in treating patients with locally advanced or regional stage IV head and neck cancer that cannot be removed by surgery.
detailed Description
OBJECTIVES: Primary * Determine 2-year progression-free survival in patients with unresectable locally advanced or regional stage IV squamous cell or undifferentiated carcinoma of the head and neck treated with cetuximab, cisplatin, and definitive radiotherapy. Secondary * Determine response rate and overall survival in patients treated with this regimen. * Determine the toxic effects of this regimen in these patients. * Correlate epidermal growth factor receptor (EGFR) expression by immunohistochemistry, EGFR phosphorylation, map kinase, Akt, signal transducer and activator of transcription 3 (STAT3), and other tissue and serum tests with toxicity of this regimen and outcomes in these patients. OUTLINE: This is a multicenter study. Patients are stratified according to tumor site (hypopharynx vs. oropharynx vs. oral cavity vs. larynx), primary tumor stage (T1-3 vs. T4), and nodal status (N0 vs. N1 vs. N2-3). * Cetuximab therapy: Patients receive an initial loading dose of cetuximab IV over 2 hours on day 1. Patients then receive cetuximab IV over 1 hour on days 8, 15, 22, 29, 36, 43, 50, and 57. * Chemoradiotherapy: Beginning on day 15 of cetuximab therapy, patients undergo radiotherapy once daily, 5 days a week, for at least 7 weeks. Patients also receive cisplatin IV over 1-2 hours on days 15, 36, and 57. * Cetuximab maintenance therapy: After the completion of chemoradiotherapy, patients continue to receive cetuximab IV over 1 hour once weekly for 6-12 months. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 months for 10 years. ACCRUAL: A total of 69 patients were accrued for this study.
Source references
references
  1. citation
    Langer CJ, Lee JW, Patel UA, et al.: Preliminary analysis of ECOG 3303: concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). [Abstract] J Clin Oncol 26 (Suppl 15): A-6006, 2008.
    type
    RESULT
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-608852ef05546ddaa67b
      requested nct id
      NCT00096174
      primary nct id
      NCT00096174
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      payload sha256
      cd19d3e0735a4654c81860d758c75477a39001ecbe41376c67ac83c97262ff84
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-608852ef05546ddaa67b
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00096174
      occurrences
      1. context exact
        NCT00096174
        end
        11
        exact text
        NCT00096174
        start
        0
      offset unit
      unicode_code_points
      query cond
      Hypopharyngeal Cancer
      query disease state id
      ds-hypopharyngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-hypopharyngeal-cancer-000.json
      source file sha256
      cd92c144c33b33e75a38086ce6cbd6e62d34b7ba84c72dacac16e6781439e40e
      source json pointer
      /studies/27/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      514dffc1b62b8f6d3962355dadc90abd99c1313e636a0364c6c9e7967c6af151
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-97b1d553f034369cd6f2
      requested nct id
      NCT00096174
      primary nct id
      NCT00096174
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      payload sha256
      14077a82ebf758e10655eaa89500666bb5260e047837e4b370a6411a746c779c
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-97b1d553f034369cd6f2
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00096174
      occurrences
      1. context exact
        NCT00096174
        end
        11
        exact text
        NCT00096174
        start
        0
      offset unit
      unicode_code_points
      query cond
      Laryngeal Cancer
      query disease state id
      ds-laryngeal-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-laryngeal-cancer-000.json
      source file sha256
      fd31a95088dd8ee475e2862bffd724180f0c754cf3f0e892cba5b448df424980
      source json pointer
      /studies/37/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      514dffc1b62b8f6d3962355dadc90abd99c1313e636a0364c6c9e7967c6af151

    Preserved source evidence · Not medical advice